Teva Pharmaceutical Industries Limited (NYSE:TEVA) EVP Matthew Shields Sells 6,206 Shares

Teva Pharmaceutical Industries Limited (NYSE:TEVA - Get Free Report) EVP Matthew Shields sold 6,206 shares of the stock in a transaction that occurred on Tuesday, June 3rd. The shares were sold at an average price of $17.02, for a total value of $105,626.12. Following the transaction, the executive vice president now owns 9,989 shares of the company's stock, valued at $170,012.78. This represents a 38.32% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

Teva Pharmaceutical Industries Trading Up 3.0%

TEVA stock traded up $0.51 during midday trading on Friday, reaching $17.76. The company's stock had a trading volume of 11,572,592 shares, compared to its average volume of 10,166,092. The company has a debt-to-equity ratio of 2.97, a quick ratio of 0.75 and a current ratio of 0.98. The stock has a fifty day simple moving average of $15.72 and a two-hundred day simple moving average of $17.39. Teva Pharmaceutical Industries Limited has a 1 year low of $12.47 and a 1 year high of $22.80. The firm has a market capitalization of $20.37 billion, a price-to-earnings ratio of -12.25, a PEG ratio of 1.44 and a beta of 0.60.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last released its earnings results on Wednesday, May 7th. The company reported $0.52 earnings per share for the quarter, topping analysts' consensus estimates of $0.47 by $0.05. Teva Pharmaceutical Industries had a positive return on equity of 42.46% and a negative net margin of 9.91%. The business had revenue of $3.89 billion for the quarter, compared to analyst estimates of $3.99 billion. During the same quarter last year, the firm posted $0.48 earnings per share. The business's revenue was up 1.9% compared to the same quarter last year. On average, equities research analysts predict that Teva Pharmaceutical Industries Limited will post 2.5 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on TEVA. Hsbc Global Res upgraded Teva Pharmaceutical Industries to a "strong-buy" rating in a research report on Monday, April 28th. Truist Financial began coverage on Teva Pharmaceutical Industries in a research report on Wednesday, May 28th. They issued a "buy" rating and a $25.00 price target for the company. Bank of America raised their price target on Teva Pharmaceutical Industries from $20.00 to $22.00 and gave the stock a "buy" rating in a research report on Thursday, May 8th. Wall Street Zen upgraded Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating in a research report on Thursday, May 22nd. Finally, The Goldman Sachs Group began coverage on Teva Pharmaceutical Industries in a research report on Friday. They issued a "buy" rating and a $24.00 price target for the company. Nine analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat, Teva Pharmaceutical Industries presently has a consensus rating of "Buy" and a consensus target price of $24.44.

Institutional Trading of Teva Pharmaceutical Industries

A number of hedge funds and other institutional investors have recently bought and sold shares of TEVA. US Bancorp DE increased its stake in shares of Teva Pharmaceutical Industries by 6.5% during the first quarter. US Bancorp DE now owns 10,812 shares of the company's stock valued at $166,000 after buying an additional 656 shares during the period. Thrivent Financial for Lutherans increased its stake in shares of Teva Pharmaceutical Industries by 0.3% during the fourth quarter. Thrivent Financial for Lutherans now owns 225,210 shares of the company's stock valued at $4,964,000 after buying an additional 699 shares during the period. Bfsg LLC increased its stake in shares of Teva Pharmaceutical Industries by 7.8% during the first quarter. Bfsg LLC now owns 10,960 shares of the company's stock valued at $168,000 after buying an additional 790 shares during the period. Townsquare Capital LLC increased its stake in shares of Teva Pharmaceutical Industries by 2.1% during the fourth quarter. Townsquare Capital LLC now owns 40,162 shares of the company's stock valued at $885,000 after buying an additional 812 shares during the period. Finally, Metis Global Partners LLC increased its stake in shares of Teva Pharmaceutical Industries by 6.7% during the fourth quarter. Metis Global Partners LLC now owns 13,697 shares of the company's stock valued at $302,000 after buying an additional 860 shares during the period. Hedge funds and other institutional investors own 54.05% of the company's stock.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.